Floatz logo

mdx2001

Cervical Cancer

ModeX Therapeutics, An OPKO Health CompanyPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

159 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Indocyanine Green
Istanbul University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 3B
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B

View all 50 →

Same molecule, other indications

mdx2001 is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
gastroesophageal cancerDormant
CC
Indicative ·
45 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →